. 2016 Feb;34(10).
doi: 10.1200/JCO.2015.65.2289.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Lyndsay N Harris 1 Nofisat Ismaila 2 Lisa M McShane 1 Fabrice Andre 1 Deborah E Collyar 1 Ana M Gonzalez-Angulo 1 Elizabeth H Hammond 1 Nicole M Kuderer 1 Minetta C Liu 1 Robert G Mennel 1 Catherine Van Poznak 1 Robert C Bast 1 Daniel F Hayes 1 American Society of Clinical Oncology  
  • PMID: 26858339
  •     78 References
  •     223 citations


Purpose: To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer.

Methods: A literature search and prospectively defined study selection sought systematic reviews, meta-analyses, randomized controlled trials, prospective-retrospective studies, and prospective comparative observational studies published from 2006 through 2014. Outcomes of interest included overall survival and disease-free or recurrence-free survival. Expert panel members used informal consensus to develop evidence-based guideline recommendations.

Results: The literature search identified 50 relevant studies. One randomized clinical trial and 18 prospective-retrospective studies were found to have evaluated the clinical utility, as defined by the guideline, of specific biomarkers for guiding decisions on the need for adjuvant systemic therapy. No studies that met guideline criteria for clinical utility were found to guide choice of specific treatments or regimens.

Recommendations: In addition to estrogen and progesterone receptors and human epidermal growth factor receptor 2, the panel found sufficient evidence of clinical utility for the biomarker assays Oncotype DX, EndoPredict, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgroups of breast cancer. No biomarker except for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 was found to guide choices of specific treatment regimens. Treatment decisions should also consider disease stage, comorbidities, and patient preferences.

Patient-centered care for older adults with multiple chronic conditions: a stepwise approach from the American Geriatrics Society: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity.
American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity.
J Am Geriatr Soc, 2012 Sep 22; 60(10). PMID: 22994844    Free PMC article.
Highly Cited.
Randomized clinical trials with biomarkers: design issues.
Boris Freidlin, Lisa M McShane, Edward L Korn.
J Natl Cancer Inst, 2010 Jan 16; 102(3). PMID: 20075367    Free PMC article.
Highly Cited.
p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients.
Maria Stendahl, Sofie Nilsson, +4 authors, Göran Landberg.
Int J Cancer, 2011 Feb 26; 127(12). PMID: 21351264
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.
S Ladoire, G Mignot, +15 authors, F Ghiringhelli.
Ann Oncol, 2012 Mar 21; 23(10). PMID: 22431701
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
James M Rae, Suzy Drury, +8 authors, ATAC trialists.
J Natl Cancer Inst, 2012 Mar 08; 104(6). PMID: 22395643    Free PMC article.
Highly Cited.
The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Yueyao Du, Qiong Zhou, +5 authors, Jinsong Lu.
Breast Cancer Res Treat, 2011 Aug 03; 129(3). PMID: 21809115
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Meredith M Regan, Brian Leyland-Jones, +18 authors, Breast International Group (BIG) 1-98 Collaborative Group.
J Natl Cancer Inst, 2012 Mar 08; 104(6). PMID: 22395644    Free PMC article.
Highly Cited.
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.
Michael Knauer, Stella Mook, +7 authors, Laura J van 't Veer.
Breast Cancer Res Treat, 2010 Mar 06; 120(3). PMID: 20204499
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
M A Province, M P Goetz, +52 authors, International Tamoxifen Pharmacogenomics Consortium.
Clin Pharmacol Ther, 2013 Sep 26; 95(2). PMID: 24060820    Free PMC article.
The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
Kirsten Vang Nielsen, Bent Ejlertsen, +4 authors, Henning T Mouridsen.
Acta Oncol, 2008 May 10; 47(4). PMID: 18465341
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
N Harbeck, M Schmitt, +12 authors, Chemo-N 0 Study Group.
Eur J Cancer, 2013 Mar 16; 49(8). PMID: 23490655
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
Lajos Pusztai, Jong-Hyeon Jeong, +8 authors, W Fraser Symmans.
J Clin Oncol, 2009 Aug 12; 27(26). PMID: 19667268    Free PMC article.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
Douglas T Ross, Chung-Yeul Kim, +7 authors, Norman Wolmark.
Clin Cancer Res, 2008 Oct 18; 14(20). PMID: 18927301    Free PMC article.
Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
P-L Jerevall, X-J Ma, +9 authors, O Stål.
Br J Cancer, 2011 May 12; 104(11). PMID: 21559019    Free PMC article.
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
G Viale, M M Regan, +17 authors, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
Ann Oncol, 2011 Feb 22; 22(10). PMID: 21335417    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
S Loi, S Michiels, +13 authors, C Sotiriou.
Ann Oncol, 2014 Mar 13; 25(8). PMID: 24608200
Highly Cited.
Clinical trial designs for predictive marker validation in cancer treatment trials.
Daniel J Sargent, Barbara A Conley, Carmen Allegra, Laurence Collette.
J Clin Oncol, 2005 Mar 19; 23(9). PMID: 15774793
Highly Cited. Review.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, +19 authors, College of American Pathologists.
J Clin Oncol, 2013 Oct 09; 31(31). PMID: 24101045
Highly Cited.
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Sherene Loi, Nicolas Sirtaine, +13 authors, Christos Sotiriou.
J Clin Oncol, 2013 Jan 24; 31(7). PMID: 23341518
Highly Cited.
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.
Ivana Sestak, Jack Cuzick, +8 authors, Michael Gnant.
J Clin Oncol, 2014 Oct 22; 33(8). PMID: 25332252
Highly Cited.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
Arch Pathol Lab Med, 2010 Jun 09; 134(6). PMID: 20524868    Free PMC article.
Highly Cited.
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.
Matthew P Goetz, Vera J Suman, +14 authors, James N Ingle.
Clin Cancer Res, 2012 Dec 06; 19(2). PMID: 23213055    Free PMC article.
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
P Dubsky, J C Brase, +18 authors, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Br J Cancer, 2013 Oct 26; 109(12). PMID: 24157828    Free PMC article.
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Mitch Dowsett, Torsten O Nielsen, +19 authors, International Ki-67 in Breast Cancer Working Group.
J Natl Cancer Inst, 2011 Oct 01; 103(22). PMID: 21960707    Free PMC article.
Highly Cited.
Breaking a vicious cycle.
Daniel F Hayes, Jeff Allen, +10 authors, Sean R Tunis.
Sci Transl Med, 2013 Aug 02; 5(196). PMID: 23903752
Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
Yi Zhang, Catherine A Schnabel, +7 authors, Mark G Erlander.
Clin Cancer Res, 2013 Jun 13; 19(15). PMID: 23757354
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
George Pentheroudakis, Konstantine T Kalogeras, +13 authors, George Fountzilas.
Breast Cancer Res Treat, 2008 Aug 01; 116(1). PMID: 18668363
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Olympia Tzaida, Helen Gogas, +14 authors, Petroula Arapantoni-Dadioti.
Oncology, 2008 Jan 12; 72(5-6). PMID: 18187961
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
Circulating tumour cells in non-metastatic breast cancer: a prospective study.
Anthony Lucci, Carolyn S Hall, +6 authors, Savitri Krishnamurthy.
Lancet Oncol, 2012 Jun 09; 13(7). PMID: 22677156
Highly Cited.
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
Kathleen I Pritchard, Alison Munro, +6 authors, John M S Bartlett.
Breast Cancer Res Treat, 2011 Nov 02; 131(2). PMID: 22042366
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
Edith A Perez, Amylou C Dueck, +12 authors, Monica M Reinholz.
J Clin Oncol, 2013 May 08; 31(17). PMID: 23650412    Free PMC article.
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Mei-Yin C Polley, Boris Freidlin, +3 authors, Lisa M McShane.
J Natl Cancer Inst, 2013 Oct 19; 105(22). PMID: 24136891    Free PMC article.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Use of archived specimens in evaluation of prognostic and predictive biomarkers.
Richard M Simon, Soonmyung Paik, Daniel F Hayes.
J Natl Cancer Inst, 2009 Oct 10; 101(21). PMID: 19815849    Free PMC article.
Highly Cited.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, +19 authors, College of American Pathologists.
Arch Pathol Lab Med, 2013 Oct 09; 138(2). PMID: 24099077    Free PMC article.
Highly Cited.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Miguel Martin, Jan C Brase, +15 authors, Alvaro Rodriguez-Lescure.
Breast Cancer Res, 2014 Apr 15; 16(2). PMID: 24725534    Free PMC article.
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
J Hannemann, P Kristel, +10 authors, M J van de Vijver.
Br J Cancer, 2006 Nov 08; 95(10). PMID: 17088909    Free PMC article.
Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.
Geoffrey S Ginsburg, Nicole M Kuderer.
J Clin Oncol, 2012 Oct 17; 30(34). PMID: 23071236    Free PMC article.
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Angelo Di Leo, Christine Desmedt, +19 authors, HER2/TOP2A Meta-analysis Study Group.
Lancet Oncol, 2011 Sep 16; 12(12). PMID: 21917518
Publication of tumor marker research results: the necessity for complete and transparent reporting.
Lisa M McShane, Daniel F Hayes.
J Clin Oncol, 2012 Oct 17; 30(34). PMID: 23071235    Free PMC article.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, +9 authors, Mitch Dowsett.
Lancet Oncol, 2013 Sep 17; 14(11). PMID: 24035531    Free PMC article.
Highly Cited.
An international Ki67 reproducibility study.
Mei-Yin C Polley, Samuel C Y Leung, +16 authors, International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group.
J Natl Cancer Inst, 2013 Nov 10; 105(24). PMID: 24203987    Free PMC article.
Highly Cited.
Distinct breast cancer subtypes in women with early-onset disease across races.
Mandeep Singh, Yi Ding, +16 authors, Peng Lee.
Am J Cancer Res, 2014 Jul 25; 4(4). PMID: 25057437    Free PMC article.
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Alvaro Moreno-Aspitia, David W Hillman, +11 authors, Edith A Perez.
Cancer, 2013 Jun 08; 119(15). PMID: 23744760    Free PMC article.
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
F P O'Malley, S Chia, +6 authors, K I Pritchard.
Breast Cancer Res Treat, 2011 Apr 27; 128(2). PMID: 21519837
Validation of 70-gene prognosis signature in node-negative breast cancer.
J M Bueno-de-Mesquita, S C Linn, +16 authors, M J van de Vijver.
Breast Cancer Res Treat, 2008 Sep 27; 117(3). PMID: 18819002
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
Scandinavian Breast Group Trial 9401, Minna Tanner, +7 authors, Jonas Bergh.
J Clin Oncol, 2006 May 10; 24(16). PMID: 16682728
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Brigitte Rack, Christian Schindlbeck, +15 authors, SUCCESS Study Group.
J Natl Cancer Inst, 2014 May 17; 106(5). PMID: 24832787    Free PMC article.
Highly Cited.
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.
Steven M Teutsch, Linda A Bradley, +7 authors, EGAPP Working Group.
Genet Med, 2008 Sep 25; 11(1). PMID: 18813139    Free PMC article.
Highly Cited.
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients.
Azadeh Stark, Gena Kucera, +2 authors, Jennifer Griggs.
Int J Qual Health Care, 2004 Nov 24; 16(6). PMID: 15557362
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials.
R Conforti, T Boulet, +9 authors, F Andre.
Ann Oncol, 2007 May 23; 18(9). PMID: 17515403
Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel.
Manfred Kaufmann, Lajos Pusztai, Biedenkopf Expert Panel Members.
Cancer, 2011 Apr 08; 117(8). PMID: 21472705
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.
M Knauer, F Cardoso, +4 authors, L J van 't Veer.
Br J Cancer, 2010 Nov 18; 103(12). PMID: 21081926    Free PMC article.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +21 authors, American Society of Clinical Oncology/College of American Pathologists.
Arch Pathol Lab Med, 2007 Jan 01; 131(1). PMID: 19548375
Highly Cited.
Ki67 in breast cancer: prognostic and predictive potential.
Rinat Yerushalmi, Ryan Woods, +2 authors, Karen A Gelmon.
Lancet Oncol, 2010 Feb 16; 11(2). PMID: 20152769
Highly Cited. Review.
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Giuseppe Viale, Anita Giobbie-Hurder, +18 authors, Breast International Group Trial 1-98.
J Clin Oncol, 2008 Nov 05; 26(34). PMID: 18981464    Free PMC article.
Highly Cited.
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
Pernille Braemer Hertel, Dongsheng Tu, +9 authors, Torsten O Nielsen.
Breast Cancer Res Treat, 2011 Dec 14; 132(1). PMID: 22160637
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
M Gnant, M Filipits, +22 authors, Austrian Breast and Colorectal Cancer Study Group.
Ann Oncol, 2013 Dec 19; 25(2). PMID: 24347518
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Martin Filipits, Torsten O Nielsen, +22 authors, Austrian Breast and Colorectal Cancer Study Group.
Clin Cancer Res, 2014 Feb 13; 20(5). PMID: 24520097
Measuring the performance of markers for guiding treatment decisions.
Holly Janes, Margaret S Pepe, Patrick M Bossuyt, William E Barlow.
Ann Intern Med, 2011 Feb 16; 154(4). PMID: 21320940    Free PMC article.
Targeting adjuvant chemotherapy: a good idea that needs to be proven!
Daniel F Hayes.
J Clin Oncol, 2012 Feb 23; 30(12). PMID: 22355050
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
D F Hayes, R C Bast, +10 authors, R J Winn.
J Natl Cancer Inst, 1996 Oct 16; 88(20). PMID: 8841020
Highly Cited. Review.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).
Jonathan F Lara, Ann D Thor, +15 authors, Cancer and Leukemia Group B.
Clin Cancer Res, 2011 Jun 23; 17(15). PMID: 21693655    Free PMC article.
Outcomes of interest in evidence-based evaluations of genetic tests.
Jeffrey R Botkin, Steven M Teutsch, +6 authors, EGAPP Working Group.
Genet Med, 2010 Feb 02; 12(4). PMID: 20118789
Long-term impact of the 70-gene signature on breast cancer outcome.
C A Drukker, H van Tinteren, +4 authors, L J Van't Veer.
Breast Cancer Res Treat, 2014 Jan 22; 143(3). PMID: 24445566    Free PMC article.
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
P Dubsky, M Filipits, +17 authors, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Ann Oncol, 2012 Oct 05; 24(3). PMID: 23035151    Free PMC article.
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Stella Mook, Marjanka K Schmidt, +10 authors, TRANSBIG Consortium.
Breast Cancer Res Treat, 2008 Jul 29; 116(2). PMID: 18661261
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients.
Carolyn S Hall, Mandar G Karhade, +4 authors, Anthony Lucci.
J Am Coll Surg, 2016 Apr 07; 223(1). PMID: 27049782    Free PMC article.
Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine.
Ana Egatz-Gomez, Ceming Wang, +6 authors, Hsueh-Chia Chang.
Biomicrofluidics, 2016 May 18; 10(3). PMID: 27190565    Free PMC article.
Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Amila Orucevic, Robert E Heidel, John L Bell.
Breast Cancer Res Treat, 2016 May 22; 157(3). PMID: 27206678    Free PMC article.
The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.
Josee-Lyne Ethier, Eitan Amir.
Mol Diagn Ther, 2016 May 29; 20(4). PMID: 27235162
Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?
David Groheux, Elif Hindié.
Eur J Nucl Med Mol Imaging, 2016 Jun 02; 43(9). PMID: 27245758
Breast cancer: The 21-gene recurrence score - biology remains at the forefront.
Shannon L Puhalla, Nancy E Davidson.
Nat Rev Clin Oncol, 2016 Jun 15; 13(8). PMID: 27296295
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives.
Jai N Patel.
Pharmgenomics Pers Med, 2016 Jul 30; 9. PMID: 27471406    Free PMC article.
Best Practices for Genomic Assay Testing in Early-Stage Breast Cancer: Clinical and Medicolegal Perspectives.
Andrew D Seidman, Darius K Amjadi, Tammy De La Melena, Darren Wheeler.
Popul Health Manag, 2016 Sep 30; 20(4). PMID: 27684734    Free PMC article.
Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.
Christopher R Friese, Yun Li, +6 authors, Steven J Katz.
Cancer, 2016 Oct 25; 123(1). PMID: 27775837    Free PMC article.
Diagnostic and prognostic value of serum MACC1 in breast cancer patients.
Weige Tan, Xinhua Xie, +12 authors, Wenbo Zheng.
Oncotarget, 2016 Oct 30; 7(51). PMID: 27793048    Free PMC article.
Genomic Disparities in Breast Cancer Among Latinas.
Filipa Lynce, Kristi D Graves, +6 authors, Susan T Vadaparampil.
Cancer Control, 2016 Nov 15; 23(4). PMID: 27842325    Free PMC article.
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
Aleix Prat, Ana Lluch, +22 authors, Emilio Alba.
Clin Cancer Res, 2016 Dec 03; 23(12). PMID: 27903675    Free PMC article.
New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies.
Rachel C Jankowitz, Steffi Oesterreich, Adrian V Lee, Nancy E Davidson.
Clin Cancer Res, 2016 Dec 17; 23(5). PMID: 27979914    Free PMC article.
Recent advances in the medical treatment of breast cancer.
Daniel A Vorobiof.
F1000Res, 2016 Dec 19; 5. PMID: 27990275    Free PMC article.
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Hyun-Seok Kim, Christopher B Umbricht, +22 authors, Leslie Cope.
J Clin Oncol, 2016 Dec 22; 34(36). PMID: 27998227    Free PMC article.
Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.
Juan Chen, Juan Xu, +9 authors, Yan Zhang.
Oncotarget, 2017 Jan 05; 8(6). PMID: 28052038    Free PMC article.
Precision medicine in early breast cancer-can this apply to radiotherapy?
Samuel G W Ow, Soo-Chin Lee.
J Thorac Dis, 2017 Jan 10; 8(11). PMID: 28066563    Free PMC article.
Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways.
Jia Wu, Yi Cui, +5 authors, Ruijiang Li.
Clin Cancer Res, 2017 Jan 12; 23(13). PMID: 28073839    Free PMC article.
Clinico-Pathologic Subtypes of Breast Cancer Primary Tumors Are Related to Prognosis after Recurrence
Cesar Sánchez, Mauricio Camus, +8 authors, Francisco Acevedo.
Asian Pac J Cancer Prev, 2017 Jan 27; 17(12). PMID: 28122438    Free PMC article.
What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer.
Melanie Majure, Aaron C Logan.
Ann Transl Med, 2017 Feb 06; 4(24). PMID: 28149904    Free PMC article.
Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Carlos H Barcenas, Akshara Raghavendra, +10 authors, Debu Tripathy.
Cancer, 2017 Feb 16; 123(13). PMID: 28199747    Free PMC article.
Epidemiology and survival outcome of breast cancer in a nationwide study.
Fu-Chao Liu, Huan-Tang Lin, +3 authors, Huang-Ping Yu.
Oncotarget, 2017 Feb 16; 8(10). PMID: 28199975    Free PMC article.
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Amila Orucevic, John L Bell, Alison P McNabb, Robert E Heidel.
Breast Cancer Res Treat, 2017 Mar 01; 163(1). PMID: 28243897    Free PMC article.
Extended Endocrine Therapy: Is 5 Years Enough?
Manali A Bhave, N Lynn Henry.
Curr Oncol Rep, 2017 Mar 03; 19(3). PMID: 28251491
Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.
Xifeng Wu, Yuanqing Ye, +11 authors, Gabriel N Hortobagyi.
J Natl Cancer Inst, 2017 Apr 05; 109(7). PMID: 28376179    Free PMC article.
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Aranzazu Fernandez-Martinez, Tomás Pascual, +30 authors, Miguel Martin.
Oncotarget, 2017 Apr 21; 8(13). PMID: 28423537    Free PMC article.
An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.
Zsuzsanna Varga, Annette Lebeau, +18 authors, Giuseppe Viale.
Breast Cancer Res, 2017 May 12; 19(1). PMID: 28490348    Free PMC article.
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
Daniel J Farrugia, Alessandra Landmann, +13 authors, Rohit Bhargava.
Mod Pathol, 2017 May 27; 30(8). PMID: 28548119
Clinical utility of gene-expression signatures in early stage breast cancer.
Maryann Kwa, Andreas Makris, Francisco J Esteva.
Nat Rev Clin Oncol, 2017 Jun 01; 14(10). PMID: 28561071
Highly Cited. Review.
Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.
Mariana Chavez-MacGregor, Elizabeth A Mittendorf, +3 authors, Sharon H Giordano.
Oncologist, 2017 Jun 09; 22(11). PMID: 28592619    Free PMC article.
Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
Ann H Partridge, Karen Sepucha, +6 authors, Bryan P Schneider.
Breast Cancer Res Treat, 2017 Jun 25; 165(3). PMID: 28646344    Free PMC article.
Making Meaningful Clinical Use of Biomarkers.
Matthew J Selleck, Maheswari Senthil, Nathan R Wall.
Biomark Insights, 2017 Jul 01; 12. PMID: 28659713    Free PMC article.
Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer.
Giuseppe Merlino, Patrizia Miodini, +3 authors, Maria Grazia Daidone.
Mol Oncol, 2017 Jul 04; 11(10). PMID: 28672102    Free PMC article.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
Ian Krop, Nofisat Ismaila, +10 authors, Vered Stearns.
J Clin Oncol, 2017 Jul 12; 35(24). PMID: 28692382    Free PMC article.
Highly Cited.
Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.
Maura Bríd Cotter, Alex Dakin, +5 authors, Cecily M Quinn.
Virchows Arch, 2017 Jul 15; 471(3). PMID: 28707056
Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology.
Elizabeth A Mittendorf, Mariana Chavez-MacGregor, +5 authors, Kelly K Hunt.
Ann Surg Oncol, 2017 Jul 21; 24(12). PMID: 28726077    Free PMC article.
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
D L Hertz, K M Kidwell, +8 authors, J M Rae.
Breast Cancer Res Treat, 2017 Jul 22; 166(1). PMID: 28730340    Free PMC article.
How to Achieve Optimal Care in Early Breast Cancer with 'Less' or 'More' Treatment.
Giuseppe Curigliano.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785179    Free PMC article.
Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy.
Ivana Sestak.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785181    Free PMC article.
The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.
O Burgués, Mª Á López-García, +4 authors, V Peg.
Clin Transl Oncol, 2017 Aug 11; 20(3). PMID: 28795336
Genomic Evolution of Breast Cancer Metastasis and Relapse.
Lucy R Yates, Stian Knappskog, +27 authors, Peter J Campbell.
Cancer Cell, 2017 Aug 16; 32(2). PMID: 28810143    Free PMC article.
Highly Cited.
Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.
Lironne Wein, Peter Savas, +3 authors, Sherene Loi.
Front Oncol, 2017 Aug 22; 7. PMID: 28824872    Free PMC article.
Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.
Ettienne J Myburgh, Lizanne Langenhoven, +2 authors, Maritha J Kotze.
J Glob Oncol, 2017 Aug 24; 3(4). PMID: 28831439    Free PMC article.
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
G Curigliano, H J Burstein, +52 authors, B Xu.
Ann Oncol, 2017 Aug 26; 28(8). PMID: 28838210    Free PMC article.
Highly Cited.
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
Melissa A Troester, Xuezheng Sun, +16 authors, Charles M Perou.
J Natl Cancer Inst, 2017 Sep 02; 110(2). PMID: 28859290    Free PMC article.
Are online prediction tools a valid alternative to genomic profiling in the context of systemic treatment of ER-positive breast cancer?
Umar Wazir, Kinan Mokbel, Amtul Carmichael, Kefah Mokbel.
Cell Mol Biol Lett, 2017 Sep 08; 22. PMID: 28878809    Free PMC article.
Validation of the 18-gene classifier as a prognostic biomarker of distant metastasis in breast cancer.
Skye Hung-Chun Cheng, Tzu-Ting Huang, +6 authors, Ben-Long Yu.
PLoS One, 2017 Sep 09; 12(9). PMID: 28886126    Free PMC article.
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +13 authors, Noa Ben-Baruch.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900632    Free PMC article.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +21 authors, Nicky Liebermann.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900633    Free PMC article.
Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few.
Paula R Pohlmann, Claudine Isaacs.
J Natl Cancer Inst, 2017 Sep 20; 110(1). PMID: 28922782    Free PMC article.
Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.
Elise Deluche, Laurence Venat-Bouvet, +6 authors, Nicole Tubiana-Mathieu.
BMC Cancer, 2017 Sep 29; 17(1). PMID: 28954632    Free PMC article.
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.
T Fujii, T Kogawa, +10 authors, N T Ueno.
Ann Oncol, 2017 Sep 30; 28(10). PMID: 28961844    Free PMC article.
Awareness and current knowledge of breast cancer.
Muhammad Akram, Mehwish Iqbal, Muhammad Daniyal, Asmat Ullah Khan.
Biol Res, 2017 Oct 04; 50(1). PMID: 28969709    Free PMC article.
Highly Cited. Review.
Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
Arian Lundberg, Linda S Lindström, +8 authors, Nicholas P Tobin.
Clin Cancer Res, 2017 Oct 04; 23(24). PMID: 28972043    Free PMC article.
ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy.
Fangbin Song, Jianbing Zhang, +6 authors, Junming Xu.
Onco Targets Ther, 2017 Oct 19; 10. PMID: 29042797    Free PMC article.
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Delphine Hequet, Céline Callens, +20 authors, Roman Rouzier.
PLoS One, 2017 Oct 19; 12(10). PMID: 29045452    Free PMC article.
Overview on Patient Centricity in Cancer Care.
Šarunas Narbutas, Kristina York, +5 authors, Andras Inotai.
Front Pharmacol, 2017 Oct 21; 8. PMID: 29051734    Free PMC article.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer.
E Nilüfer Güler.
Eur J Breast Health, 2017 Oct 31; 13(4). PMID: 29082373    Free PMC article.
Electronic Health Record Phenotypes for Precision Medicine: Perspectives and Caveats From Treatment of Breast Cancer at a Single Institution.
Matthew K Breitenstein, Hongfang Liu, +2 authors, Rui Zhang.
Clin Transl Sci, 2017 Oct 31; 11(1). PMID: 29084368    Free PMC article.
Clinical utility of multigene profiling assays in early-stage breast cancer.
M C Chang, L H Souter, +6 authors, Molecular Oncology Advisory Committee.
Curr Oncol, 2017 Nov 02; 24(5). PMID: 29089811    Free PMC article.
Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.
Jose Jeronimo, Philip E Castle, +12 authors, Surendra S Shastri.
J Glob Oncol, 2017 Nov 03; 3(5). PMID: 29094101    Free PMC article.
Highly Cited.
A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer.
Gen Wang, Xiaosong Chen, +2 authors, Kunwei Shen.
Transl Oncol, 2017 Nov 03; 10(6). PMID: 29096247    Free PMC article.
Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay.
Sung Gwe Ahn, Soong June Bae, +4 authors, Joon Jeong.
PLoS One, 2017 Nov 09; 12(11). PMID: 29117208    Free PMC article.
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, +9 authors, EBCTCG.
N Engl J Med, 2017 Nov 09; 377(19). PMID: 29117498    Free PMC article.
Highly Cited.
Molecular Subtypes and Local-Regional Control of Breast Cancer.
Simona Maria Fragomeni, Andrew Sciallis, Jacqueline S Jeruss.
Surg Oncol Clin N Am, 2017 Nov 15; 27(1). PMID: 29132568    Free PMC article.
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Maria Vittoria Dieci, Valentina Guarneri, +15 authors, PierFranco Conte.
Oncologist, 2017 Nov 15; 23(3). PMID: 29133514    Free PMC article.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis.
Vasily N Aushev, Eunjee Lee, +11 authors, Jia Chen.
Clin Cancer Res, 2017 Nov 16; 24(3). PMID: 29138345    Free PMC article.
The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.
Michaela Aubele, Manfred Schmitt, +8 authors, Marion Kiechle.
Dis Markers, 2017 Nov 16; 2017. PMID: 29138528    Free PMC article.
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.
Ling Xin, Yin-Hua Liu, Tracey A Martin, Wen G Jiang.
World J Oncol, 2017 Nov 18; 8(2). PMID: 29147432    Free PMC article.
Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients.
Johanna Oltmann, Kerstin Heselmeyer-Haddad, +15 authors, Thomas Ried.
Genes Chromosomes Cancer, 2017 Nov 29; 57(4). PMID: 29181861    Free PMC article.
Large-scale DNA organization is a prognostic marker of breast cancer survival.
Martial Guillaud, Qian Ye, +5 authors, Mira Keyes.
Med Oncol, 2017 Dec 08; 35(1). PMID: 29214466
Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.
Anna Weiss, Mariana Chavez-MacGregor, +6 authors, Elizabeth A Mittendorf.
JAMA Oncol, 2017 Dec 10; 4(2). PMID: 29222540    Free PMC article.
Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy.
Jacques Raphael, S Nofech-Mozes, +2 authors, S Gandhi.
Pathol Oncol Res, 2017 Dec 10; 25(4). PMID: 29222623
Protein biomarkers for subtyping breast cancer and implications for future research.
Claudius Mueller, Amanda Haymond, +2 authors, Virginia Espina.
Expert Rev Proteomics, 2017 Dec 23; 15(2). PMID: 29271260    Free PMC article.
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
R Colomer, I Aranda-López, +7 authors, J Palacios-Calvo.
Clin Transl Oncol, 2017 Dec 24; 20(7). PMID: 29273958    Free PMC article.
Tumor Heterogeneity in Breast Cancer.
Gulisa Turashvili, Edi Brogi.
Front Med (Lausanne), 2017 Dec 26; 4. PMID: 29276709    Free PMC article.
Highly Cited. Review.
The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Satbir Singh Thakur, Haocheng Li, +5 authors, Hua Yang.
PLoS One, 2018 Jan 06; 13(1). PMID: 29304138    Free PMC article.
Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer.
Maurizio Callari, Matteo Dugo, +4 authors, Vera Cappelletti.
Int J Mol Sci, 2018 Jan 10; 19(1). PMID: 29315233    Free PMC article.
PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Magdalena Absmaier, Rudolf Napieralski, +9 authors, Manfred Schmitt.
Int J Oncol, 2018 Jan 13; 52(3). PMID: 29328369    Free PMC article.
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
Jame Abraham, Humberto Caldera, +11 authors, Chuck Vogel.
Breast Cancer Res Treat, 2018 Jan 21; 169(1). PMID: 29352368    Free PMC article.
A Model of Dormant-Emergent Metastatic Breast Cancer Progression Enabling Exploration of Biomarker Signatures.
Amanda M Clark, Manu P Kumar, +6 authors, Alan Wells.
Mol Cell Proteomics, 2018 Jan 22; 17(4). PMID: 29353230    Free PMC article.
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Sofia Torres, Maureen Trudeau, +7 authors, Andrea Eisen.
Oncologist, 2018 Jan 27; 23(7). PMID: 29371476    Free PMC article.
Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.
Stephen M Schleicher, Maura N Dickler.
Curr Breast Cancer Rep, 2018 Feb 06; 9(4). PMID: 29399271    Free PMC article.
Metabolic Footprints and Molecular Subtypes in Breast Cancer.
Vera Cappelletti, Egidio Iorio, +3 authors, Maria Grazia Daidone.
Dis Markers, 2018 Feb 13; 2017. PMID: 29434411    Free PMC article.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, +9 authors, Mitch Dowsett.
JAMA Oncol, 2018 Feb 17; 4(4). PMID: 29450494    Free PMC article.
Highly Cited.
Luminal A Breast Cancer and Molecular Assays: A Review.
Jennifer J Gao, Sandra M Swain.
Oncologist, 2018 Feb 24; 23(5). PMID: 29472313    Free PMC article.
Spotlight on the utility of the Oncotype DX® breast cancer assay.
Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann.
Int J Womens Health, 2018 Mar 06; 10. PMID: 29503586    Free PMC article.
Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.
Onur Esbah, Berna Oksuzoglu.
Indian J Med Res, 2018 Mar 08; 146(5). PMID: 29512598    Free PMC article.
Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline.
Kelley D Mayden.
J Adv Pract Oncol, 2016 Sep 01; 7(6). PMID: 29588871    Free PMC article.
Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals.
Purificación Martínez Del Prado, Isabel Alvarez-López, +7 authors, Javier Mar.
Clinicoecon Outcomes Res, 2018 Mar 30; 10. PMID: 29593426    Free PMC article.
Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
Jonathan Chen, Xian Wu, +2 authors, Himanshu Nagar.
Breast Cancer Res, 2018 Apr 18; 20(1). PMID: 29661221    Free PMC article.
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Mitch Dowsett, Ivana Sestak, +5 authors, Jack Cuzick.
J Clin Oncol, 2018 Apr 21; 36(19). PMID: 29676944    Free PMC article.
Precision Medicine in Hormone Receptor-Positive Breast Cancer.
Azadeh Nasrazadani, Roby A Thomas, Steffi Oesterreich, Adrian V Lee.
Front Oncol, 2018 May 22; 8. PMID: 29780747    Free PMC article.
Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer.
Chelain R Goodman, Brandon-Luke L Seagle, +8 authors, Jonathan B Strauss.
JAMA Oncol, 2018 May 26; 4(8). PMID: 29800954    Free PMC article.
Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer.
Wei Li, Takashi Tanikawa, +15 authors, Weiping Zou.
Cell Metab, 2018 May 29; 28(1). PMID: 29805099    Free PMC article.
Highly Cited.
Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells.
Stefano Volinia, Valeria Bertagnolo, +18 authors, Silvano Capitani.
Oncotarget, 2018 May 29; 9(34). PMID: 29805754    Free PMC article.
Comparison of Pathological Prognostic Stage and Anatomic Stage Groups According to the Updated Version of the American Joint Committee on Cancer (AJCC) Breast Cancer Staging 8th Edition.
Kamuran Ibis, Selnur Ozkurt, +2 authors, Pınar Saip.
Med Sci Monit, 2018 Jun 01; 24. PMID: 29849016    Free PMC article.
Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment.
Eleanor E R Harris.
Int J Breast Cancer, 2018 Jun 05; 2018. PMID: 29862084    Free PMC article.
Immune cell profiling in cancer: molecular approaches to cell-specific identification.
Yasmin A Lyons, Sherry Y Wu, +2 authors, Anil K Sood.
NPJ Precis Oncol, 2018 Jun 07; 1(1). PMID: 29872708    Free PMC article.
Highly Cited. Review.
Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.
S K L Chia.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910655    Free PMC article.
Radiomics in Oncological PET/CT: Clinical Applications.
Jeong Won Lee, Sang Mi Lee.
Nucl Med Mol Imaging, 2018 Jun 27; 52(3). PMID: 29942396    Free PMC article.
Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer.
Jae-Myung Kim, Jai Min Ryu, +6 authors, Jeong Eon Lee.
J Breast Cancer, 2018 Jul 03; 21(2). PMID: 29963119    Free PMC article.
Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Danielle M Bello, Christy Russell, +2 authors, Monica Morrow.
Ann Surg Oncol, 2018 Jul 04; 25(10). PMID: 29968028    Free PMC article.
Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
Martin Sjöström, Johan Staaf, +6 authors, Irma Fredriksson.
Breast Cancer Res, 2018 Jul 06; 20(1). PMID: 29973242    Free PMC article.
Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.
Yismeilin R Feliz-Mosquea, Ashley A Christensen, +13 authors, David R Soto-Pantoja.
Breast Cancer Res Treat, 2018 Jul 30; 172(1). PMID: 30056566    Free PMC article.
Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.
Audree B Tadros, Hannah Y Wen, Monica Morrow.
Ann Surg Oncol, 2018 Aug 11; 25(11). PMID: 30094484    Free PMC article.
Adherence to guidelines in requesting Oncotype DX in a publicly funded health care system.
S Martel, M Lambertini, +2 authors, C Prady.
Curr Oncol, 2018 Aug 17; 25(4). PMID: 30111977    Free PMC article.
Co-expressed genes enhance precision of receptor status identification in breast cancer patients.
Michael Kenn, Dan Cacsire Castillo-Tong, +3 authors, Wolfgang Schreiner.
Breast Cancer Res Treat, 2018 Aug 18; 172(2). PMID: 30117066    Free PMC article.
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, +2 authors, Kathy S Albain.
NPJ Breast Cancer, 2018 Aug 30; 4. PMID: 30155517    Free PMC article.
Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
Hans-Ullrich Völker, Michael Weigel, Annette Strehl, Lea Frey.
Diagn Pathol, 2018 Sep 02; 13(1). PMID: 30170623    Free PMC article.
Trends in breast cancer mortality by stage at diagnosis among young women in the United States.
Fangjian Guo, Yong-Fang Kuo, +2 authors, Abbey B Berenson.
Cancer, 2018 Sep 07; 124(17). PMID: 30189117    Free PMC article.
MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers.
Ilaria Plantamura, Giulia Cosentino, Alessandra Cataldo.
Front Oncol, 2018 Sep 21; 8. PMID: 30234015    Free PMC article.
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.
André Filipe Vieira, Fernando Schmitt.
Front Med (Lausanne), 2018 Sep 21; 5. PMID: 30234119    Free PMC article.
Oncotype testing in patients undergoing intraoperative radiation for breast cancer.
Kelsey E Larson, Stephanie A Valente, +7 authors, Stephen R Grobmyer.
Mol Clin Oncol, 2018 Oct 23; 9(5). PMID: 30345048    Free PMC article.
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.
Wenyong Tan, Ming Yang, +2 authors, Weixi Shen.
Cancer Manag Res, 2018 Oct 24; 10. PMID: 30349367    Free PMC article.
Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status.
Sunny Dhadlie, Joseph Whitfield, Rasika Hendahewa.
Int J Surg Case Rep, 2018 Nov 06; 53. PMID: 30391732    Free PMC article.
Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer.
Gabriele Schricker, Rudolf Napieralski, +12 authors, Olaf G Wilhelm.
Sci Rep, 2018 Nov 18; 8(1). PMID: 30442983    Free PMC article.
Lymph Nodes in Breast Cancer - What Can We Learn from Translational Research?
Florentia Peintinger, Roland Reitsamer, +2 authors, Cornelia Liedtke.
Breast Care (Basel), 2018 Dec 01; 13(5). PMID: 30498419    Free PMC article.
Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer.
Carina Forsare, Martin Bak, +8 authors, Mårten Fernö.
BMC Cancer, 2018 Dec 12; 18(1). PMID: 30526533    Free PMC article.
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
Jennifer D Brooks, Elizabeth A Comen, +13 authors, Jonine L Bernstein.
Breast Cancer Res, 2018 Dec 12; 20(1). PMID: 30526633    Free PMC article.
Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis.
Shuning Ding, Jiayi Wu, +6 authors, Li Zhu.
Oncologist, 2019 Apr 26; 24(11). PMID: 31019021    Free PMC article.
From latency to overt bone metastasis in breast cancer: potential for treatment and prevention.
Fernando Salvador, Alicia Llorente, Roger R Gomis.
J Pathol, 2019 May 17; 249(1). PMID: 31095738    Free PMC article.
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Maria Vittoria Dieci, Valentina Guarneri, +16 authors, Veneto Oncology Network.
Oncologist, 2019 Jun 04; 24(11). PMID: 31152079    Free PMC article.
Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk.
Jin You Kim, Jin Joo Kim, +8 authors, Robert Grimm.
Eur Radiol, 2019 Aug 07; 30(1). PMID: 31385051
Panoptic View of Prognostic Models for Personalized Breast Cancer Management.
Geetanjali Saini, Karuna Mittal, +3 authors, Ritu Aneja.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500225    Free PMC article.
21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.
Wei Wang, Lin Lin, +11 authors, Kunwei Shen.
Oncol Lett, 2019 Oct 04; 18(4). PMID: 31579428    Free PMC article.
Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel.
Barbara Pasculli, Raffaela Barbano, +11 authors, Paola Parrella.
Sci Rep, 2019 Oct 19; 9(1). PMID: 31624308    Free PMC article.
Two Distinct Subtypes Revealed in Blood Transcriptome of Breast Cancer Patients With an Unsupervised Analysis.
Wenlong Ming, Hui Xie, +7 authors, Wanjun Gu.
Front Oncol, 2019 Oct 22; 9. PMID: 31632916    Free PMC article.
IHC Color Histograms for Unsupervised Ki67 Proliferation Index Calculation.
Rokshana S Geread, Peter Morreale, +4 authors, April Khademi.
Front Bioeng Biotechnol, 2019 Oct 22; 7. PMID: 31632956    Free PMC article.
The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study.
Tim C de Ruijter, Kim M Smits, +7 authors, Vivianne C G Tjan-Heijnen.
Diagn Progn Res, 2019 Oct 24; 3. PMID: 31641693    Free PMC article.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
Po-Sheng Yang, Yi-Hsuan Lee, +9 authors, Chiun-Sheng Huang.
Jpn J Clin Oncol, 2019 Jul 10; 49(11). PMID: 31287883    Free PMC article.
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
J M S Bartlett, D C Sgroi, +8 authors, D W Rea.
Ann Oncol, 2019 Sep 11; 30(11). PMID: 31504126    Free PMC article.
BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis.
Jasdeep Mann, Ning Yang, +3 authors, Ing Swie Goping.
Sci Rep, 2020 Jan 17; 10(1). PMID: 31942016    Free PMC article.
Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.
Jane Meisel, Chao Zhang, +7 authors, Xiaoxian Li.
Clin Breast Cancer, 2018 Jan 07; 18(5). PMID: 29305309    Free PMC article.
Metastatic Conditioning of Myeloid Cells at a Subcutaneous Synthetic Niche Reflects Disease Progression and Predicts Therapeutic Outcomes.
Robert S Oakes, Grace G Bushnell, +11 authors, Lonnie D Shea.
Cancer Res, 2019 Oct 31; 80(3). PMID: 31662327    Free PMC article.
Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Jennifer Zeng, Salvatore Piscuoglio, +7 authors, Marcia Edelweiss.
Cancer Cytopathol, 2019 Dec 29; 128(2). PMID: 31883437    Free PMC article.
Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
Angela Mariotto, Jinani Jayasekerea, +5 authors, Jeanne S Mandelblatt.
J Natl Cancer Inst, 2019 Jun 06; 112(2). PMID: 31165854    Free PMC article.
Designing Highly Crystalline Multifunctional Multicolor Luminescence Nanosystem for Tracking Breast Cancer Heterogeneity.
Avijit Pramanik, Salma Begum, +11 authors, Paresh Chandra Ray.
Nanoscale Adv, 2019 Sep 24; 1(3). PMID: 31544171    Free PMC article.
Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.
Johan Vallon-Christersson, Jari Häkkinen, +12 authors, Johan Staaf.
Sci Rep, 2019 Aug 23; 9(1). PMID: 31434940    Free PMC article.
Assessment of the Prognostic Staging System of American Joint Committee on Cancer 8th Edition for Breast Cancer: Comparisons with the Conventional Anatomic Staging System.
Eun Jin Kim, Hyung Seok Park, +3 authors, Byeong-Woo Park.
J Breast Cancer, 2020 Mar 07; 23(1). PMID: 32140270    Free PMC article.
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Joseph Sparano, Anne O'Neill, +5 authors, Kathy D Miller.
JAMA Oncol, 2018 Jul 29; 4(12). PMID: 30054636    Free PMC article.
Highly Cited.
Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives.
Suzanne C O'Neill, Kathryn L Taylor, +5 authors, Jeanne Mandelblatt.
J Health Commun, 2018 Aug 22; 23(7). PMID: 30130477    Free PMC article.
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Kathleen Van Asten, Laurence Slembrouck, +16 authors, Patrick Neven.
Oncologist, 2018 Sep 02; 24(2). PMID: 30171067    Free PMC article.
Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual.
Jennifer K Plichta, Yi Ren, +5 authors, E Shelley Hwang.
Ann Surg, 2018 Oct 13; 271(1). PMID: 30312199    Free PMC article.
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
Oscar M Rueda, Stephen-John Sammut, +21 authors, Christina Curtis.
Nature, 2019 Mar 15; 567(7748). PMID: 30867590    Free PMC article.
Highly Cited.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer.
Dat T Vo, Narasimha Kumar Karanam, +5 authors, Michael D Story.
Neoplasia, 2019 Jul 22; 21(9). PMID: 31325708    Free PMC article.
The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Jeanine Marie Nardin, Werner Schroth, +11 authors, José Claudio Casali-da-Rocha.
Clin Transl Sci, 2019 Oct 02; 13(2). PMID: 31573754    Free PMC article.
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis.
Carmen Elena Condrat, Dana Claudia Thompson, +6 authors, Silviu Cristian Voinea.
Cells, 2020 Jan 26; 9(2). PMID: 31979244    Free PMC article.
The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer.
Hirah Rizki, Christopher Hillyar, Omar Abbassi, Sascha Miles-Dua.
Cureus, 2020 Mar 21; 12(3). PMID: 32195072    Free PMC article.
Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients.
Cynthia Villarreal-Garza, Edna Anakarenn Lopez-Martinez, +9 authors, Veronica Bautista-Piña.
PLoS One, 2020 Mar 12; 15(3). PMID: 32160201    Free PMC article.
Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score.
Weiqi Gao, Lin Lin, +2 authors, Kunwei Shen.
J Cancer, 2020 Mar 24; 11(9). PMID: 32201521    Free PMC article.
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Valerie E Crolley, Husam Marashi, +12 authors, Judy King.
Breast Cancer Res Treat, 2020 Mar 15; 180(3). PMID: 32170635    Free PMC article.
A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer.
Jim Kallarackal, Florian Burger, +2 authors, Martina Schad.
PLoS One, 2020 Mar 21; 15(3). PMID: 32196521    Free PMC article.
Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice.
Rashmi K Murthy, Juhee Song, +8 authors, Gabriel N Hortobagyi.
NPJ Breast Cancer, 2020 Mar 29; 6. PMID: 32219153    Free PMC article.
The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer.
Atilla Soran, Kaori Tane, Efe Sezgin, Rohit Bhargava.
Eur J Breast Health, 2020 Apr 15; 16(2). PMID: 32285033    Free PMC article.
Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26.
Bradley M Turner, Mary Ann Gimenez-Sanders, +6 authors, David G Hicks.
Cancer Med, 2019 Jun 15; 8(9). PMID: 31199586    Free PMC article.
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Olivia Pagani, Prudence A Francis, +13 authors, SOFT and TEXT Investigators and International Breast Cancer Study Group.
J Clin Oncol, 2019 Oct 17; 38(12). PMID: 31618131    Free PMC article.
Application of magnetic nanoparticles in nucleic acid detection.
Congli Tang, Ziyu He, +10 authors, Nongyue He.
J Nanobiotechnology, 2020 Apr 23; 18(1). PMID: 32316985    Free PMC article.
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Ryan J O Dowling, Kevin Kalinsky, +29 authors, Pamela J Goodwin.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337479    Free PMC article.
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.
Ioannis Zerdes, Emmanouil G Sifakis, +6 authors, Theodoros Foukakis.
Mol Oncol, 2020 Mar 03; 14(5). PMID: 32115850    Free PMC article.
Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Christopher Hillyar, Hirah Rizki, +4 authors, Simon Smith.
Cureus, 2020 May 10; 12(4). PMID: 32382456    Free PMC article.
The RNA binding protein CPEB2 regulates hormone sensing in mammary gland development and luminal breast cancer.
Rosa Pascual, Judit Martín, +9 authors, Raúl Méndez.
Sci Adv, 2020 May 23; 6(20). PMID: 32440535    Free PMC article.
Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers.
Jieqiang Zhu, Levan Muskhelishvili, +2 authors, Minjun Chen.
Sci Rep, 2020 May 20; 10(1). PMID: 32424219    Free PMC article.
21-Gene Recurrence Score Adds Significant Value for Grade 3 Breast Cancers: Results From a National Cohort.
J Bryan Iorgulescu, Rachel A Freedman, +2 authors, Jane E Brock.
JCO Precis Oncol, 2019 Jan 01; 3. PMID: 32457931    Free PMC article.
Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Front Oncol, 2020 Jun 02; 10. PMID: 32477946    Free PMC article.
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer.
K Almstedt, S Mendoza, +9 authors, M Schmidt.
Breast Cancer Res Treat, 2020 May 22; 182(1). PMID: 32436145    Free PMC article.
Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab.
Ran Ran, Wenfa Huang, +8 authors, Huiping Li.
Onco Targets Ther, 2020 Jun 18; 13. PMID: 32547071    Free PMC article.
Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
T M Aherne, M R Boland, +4 authors, K J Sweeney.
Surg J (N Y), 2020 Jun 25; 6(2). PMID: 32577529    Free PMC article.
Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
Jason Rotter, Lauren Wilson, +2 authors, Michaela Dinan.
Breast Cancer Res Treat, 2019 Apr 28; 176(2). PMID: 31028607    Free PMC article.
Management of hormone receptor-positive, HER2-negative early breast cancer.
Elaine M Walsh, Karen L Smith, Vered Stearns.
Semin Oncol, 2020 Jun 18; 47(4). PMID: 32546323    Free PMC article.
Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer.
Fei Wang, Sonya Reid, +6 authors, Xiao-Ou Shu.
Clin Cancer Res, 2019 Nov 22; 26(1). PMID: 31748278    Free PMC article.
The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review.
Sophie Gordon-Craig, Ruth M Parks, Kwok-Leung Cheung.
Oncol Ther, 2020 Jul 24; 8(2). PMID: 32700048    Free PMC article.
Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
Vincent Walter, Chiara Fischer, +10 authors, Markus Wallwiener.
Breast Cancer Res Treat, 2020 Jul 03; 183(1). PMID: 32613540    Free PMC article.
Correlation between salivary and serum CA15-3 concentrations in patients with breast cancer.
Daniele Xavier Assad, Elisa Cançado Porto Mascarenhas, +6 authors, Eliete Neves Silva Guerra.
Mol Clin Oncol, 2020 Jul 28; 13(2). PMID: 32714539    Free PMC article.
Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.
Alberto Zambelli, Edda Simoncini, +11 authors, Carlo Tondini.
Breast, 2020 Apr 24; 52. PMID: 32325372    Free PMC article.
Overview of Breast Cancer and Implications of Overtreatment of Early-Stage Breast Cancer: An Indian Perspective.
Gouri Shankar Bhattacharyya, Dinesh C Doval, +3 authors, S P Somashekhar.
JCO Glob Oncol, 2020 Jun 09; 6. PMID: 32511068    Free PMC article.
Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence - a systematic review and meta-analysis.
Susanna M Wallerstedt, Astrid Nilsson Ek, +3 authors, Barbro Linderholm.
Eur J Clin Pharmacol, 2020 Jun 07; 76(9). PMID: 32504183    Free PMC article.
Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
Sarah M Bernhardt, Pallave Dasari, +6 authors, Wendy V Ingman.
Breast Cancer Res, 2020 Aug 20; 22(1). PMID: 32811558    Free PMC article.
Identification of a Six-lncRNA Signature With Prognostic Value for Breast Cancer Patients.
Erjie Zhao, Yujia Lan, +5 authors, Jing Hu.
Front Genet, 2020 Aug 28; 11. PMID: 32849766    Free PMC article.
Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay.
Hatem Soliman, Darl D Flake, +10 authors, William Gradishar.
JCO Precis Oncol, 2020 Sep 12; 3. PMID: 32914026    Free PMC article.
CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer.
Alexander Ring, Cu Nguyen, +5 authors, Julie E Lang.
Cancers (Basel), 2018 Dec 24; 10(12). PMID: 30572639    Free PMC article.
Single-cell analysis of tumors: Creating new value for molecular biomarker discovery of cancer stem cells and tumor-infiltrating immune cells.
Ramin Radpour, Farzad Forouharkhou.
World J Stem Cells, 2019 Jan 12; 10(11). PMID: 30631391    Free PMC article.
HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women.
Nguiessan Alphonse Aman, Brahima Doukoure, +4 authors, Ahoua Benjamin Effi.
BMC Clin Pathol, 2019 Jan 25; 19. PMID: 30675127    Free PMC article.
Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis.
Nan Shao, Chuanbo Xie, +6 authors, Ying Lin.
Cancer Manag Res, 2019 Mar 14; 11. PMID: 30863154    Free PMC article.
Breast Cancer Metabolomics: From Analytical Platforms to Multivariate Data Analysis. A Review.
Catarina Silva, Rosa Perestrelo, +2 authors, José S Câmara.
Metabolites, 2019 May 28; 9(5). PMID: 31121909    Free PMC article.
Should a Multigene Signature be Used in all Luminal Early Breast Cancers.
Nawale Hajjaji, Yves Marie Robin, Jacques Bonneterre.
Front Oncol, 2019 Jun 20; 9. PMID: 31214499    Free PMC article.
New UPLC-MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patients.
Christine Bobin-Dubigeon, Mario Campone, +3 authors, Jean-Marie Bard.
Future Sci OA, 2019 Jun 28; 5(5). PMID: 31245038    Free PMC article.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Mi Jeong Kwon, Jeong Eon Lee, +12 authors, Young Kee Shin.
Front Oncol, 2019 Aug 14; 9. PMID: 31404265    Free PMC article.
Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the International Immuno-Oncology Biomarkers Working Group.
Jiu-Yang Liu, Gui-Fang Yang, Fang-Fang Chen, Chun-Wei Peng.
Cancer Manag Res, 2019 Aug 24; 11. PMID: 31440080    Free PMC article.
Endocrine Therapy in Early Breast Cancer.
Katja Krauss, Elmar Stickeler.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982643    Free PMC article.
Validation of the Prognostic Stage of American Joint Committee on Cancer Eighth Edition Staging Manual in Invasive Lobular Carcinoma Compared to Invasive Ductal Carcinoma and Proposal of a Novel Score System.
Shuning Ding, Yu Zong, +8 authors, Li Zhu.
Front Oncol, 2020 Oct 06; 10. PMID: 33014784    Free PMC article.
Considerations for feature selection using gene pairs and applications in large-scale dataset integration, novel oncogene discovery, and interpretable cancer screening.
Laura Moody, Hong Chen, Yuan-Xiang Pan.
BMC Med Genomics, 2020 Oct 23; 13(Suppl 10). PMID: 33087122    Free PMC article.
First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.
Johannes Ettl, Sophie-Isabelle Anders, +5 authors, Marion Kiechle.
Arch Gynecol Obstet, 2020 Sep 10; 302(6). PMID: 32902674    Free PMC article.
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Hee Kyung Kim, Kyung Hee Park, +10 authors, Yeon Hee Park.
Cancer Res Treat, 2018 Sep 08; 51(2). PMID: 30189722    Free PMC article.
Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
Dinja T Kruger, Karin J Beelen, +4 authors, Sabine C Linn.
Br J Cancer, 2018 Oct 06; 119(7). PMID: 30287915    Free PMC article.
Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary?
Anne Grabenstetter, Edi Brogi, +4 authors, Hannah Y Wen.
Ann Surg Oncol, 2018 Oct 10; 26(2). PMID: 30298311    Free PMC article.
The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations.
Laura Panattoni, Tracy A Lieu, +5 authors, Scott D Ramsey.
Breast Cancer Res Treat, 2018 Oct 12; 173(2). PMID: 30306429    Free PMC article.
Benefits of introduction of Oncotype DX® testing.
N Green, A Al-Allak, C Fowler.
Ann R Coll Surg Engl, 2018 Oct 17; 101(1). PMID: 30322288    Free PMC article.
Predictability of human differential gene expression.
Megan Crow, Nathaniel Lim, +2 authors, Jesse Gillis.
Proc Natl Acad Sci U S A, 2019 Mar 09; 116(13). PMID: 30846554    Free PMC article.
[Update of the German S3 breast cancer guideline : What is new for pathologists?]
A Lebeau, C Denkert, +2 authors, A Wöckel.
Pathologe, 2019 Mar 09; 40(2). PMID: 30847505
Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers: Preliminary results for correlation with Oncotype DX recurrence scores.
Kyung Jin Nam, Hyunjin Park, +3 authors, Jeong Eon Lee.
Medicine (Baltimore), 2019 Jun 07; 98(23). PMID: 31169691    Free PMC article.
Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer.
Bruno Märkl, Martin Kazik, +7 authors, Daniel Oruzio.
BMC Cancer, 2019 Jul 17; 19(1). PMID: 31307406    Free PMC article.
Genomics applied to the treatment of breast cancer.
Diaddin Hamdan, Thi Thuy Nguyen, +3 authors, Guilhem Bousquet.
Oncotarget, 2019 Aug 16; 10(46). PMID: 31413819    Free PMC article.
Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study.
Suleyman Ozkan Aksoy, Ali İbrahim Sevinc, +6 authors, Büşra Emir.
Medicine (Baltimore), 2020 Dec 09; 99(49). PMID: 33285770    Free PMC article.
Hormonal modulation of ESR1 mutant metastasis.
Guowei Gu, Lin Tian, +28 authors, Suzanne A W Fuqua.
Oncogene, 2020 Dec 17; 40(5). PMID: 33323970
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.
Camille Moreau-Bachelard, Loïc Campion, +6 authors, Jean-Sébastien Frénel.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33322473    Free PMC article.
A novel immune prognostic index for stratification of high-risk patients with early breast cancer.
Hannah Lee, Mi Jeong Kwon, +3 authors, Young Kee Shin.
Sci Rep, 2021 Jan 10; 11(1). PMID: 33420250    Free PMC article.
Evaluating overall survival and competing risks of survival in patients with early-stage breast cancer using a comprehensive nomogram.
Yan-Bo Xu, Hong Liu, +3 authors, Dong Xu.
Cancer Med, 2020 Apr 22; 9(12). PMID: 32314546    Free PMC article.
Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.
Ping Zhou, Wen-Wen Zhang, +4 authors, San-Gang Wu.
Breast, 2020 Dec 06; 54. PMID: 33278648    Free PMC article.
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.
Peng Qi, Yu Yang, +5 authors, Xiao-Yan Zhou.
Breast Cancer Res Treat, 2021 Jan 14;. PMID: 33439420    Free PMC article.
MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines.
Wafaa M Rashed, Mohamed A Kandeil, +3 authors, Mohamed H Abdel-Rahman.
J Cancer Res Clin Oncol, 2020 Sep 28; 147(1). PMID: 32980960    Free PMC article.
Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
Inderjeet Singh, Anshul Attrey, +2 authors, Vinu Jose.
Clin Drug Investig, 2020 Nov 26; 41(1). PMID: 33236287
Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Adriane F Evangelista, Renato J Oliveira, +3 authors, Marcia M C Marques.
BMC Cancer, 2021 Jan 20; 21(1). PMID: 33461524    Free PMC article.
Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar.
Suzanne C O'Neill, Susan T Vadaparampil, +9 authors, Susan Eggly.
Patient Educ Couns, 2020 Sep 10; 104(2). PMID: 32900604    Free PMC article.

;. PMID: 33574250
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Paolo Giorgi Rossi, Annette Lebeau, +13 authors, ECIBC Contributor Group.
Br J Cancer, 2021 Feb 19;. PMID: 33597715
A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling.
Ainhoa Arana Echarri, Mark Beresford, +6 authors, James E Turner.
Front Immunol, 2021 Feb 19; 11. PMID: 33597950    Free PMC article.
Decision theory for precision therapy of breast cancer.
Michael Kenn, Dan Cacsire Castillo-Tong, +4 authors, Wolfgang Schreiner.
Sci Rep, 2021 Feb 21; 11(1). PMID: 33608588